Back

Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?

26 August 2022 (15:15 - 16:00)
Organised by:
Congress Presentation Part of: Heart failure pharmacotherapy - Sacubitril/valsartan Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Gustavo Manuel Oliveira Campos

University Hospitals of Coimbra, Coimbra (Portugal)

7 More presentations in this session

Presentation thumbnail
Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan
Assistant Professor A. Giannoni (Pisa, IT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides
Presentation thumbnail
Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials
Professor A. Hernandez (Storrs, US)
Abstract Slides
Presentation thumbnail
Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)
Assistant Professor K. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients
Doctor H. Schwende (Basel, CH)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacotherapy - Sacubitril/valsartan

The Event

Event poster

ESC Congress 2022

26 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources